An overview of growth hormone therapy in pediatric cases documented in the Kabi International Growth Study (Pfizer International Growth Database)

Author: Mitchell E. GEFFNER ¹ ; Michael B. RANKE ; Michael P. WAJNRAJCH ;
Author Information

1. The Saban Research Institute, Children’s Hospital Los Angeles, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA
Publication Type:Review Article
From:Annals of Pediatric Endocrinology & Metabolism 2024;29(1):3-11
CountryRepublic of Korea
Language:English
Abstract: The Kabi International Growth Study (KIGS) was first established in 1987 and is the largest pharmaco-epidemiological study of recombinant human growth hormone (rhGH). KIGS is aimed at evaluating long-term safety and treatment outcomes in pediatric subjects who received Genotropin rhGH therapy (Pfizer, New York, NY, USA) as prescribed by physicians in real-world clinical practice settings. KIGS data have been used to answer multiple research questions related to growth, growth prediction, and growth hormone treatment, leading to the publication of 129 peer-reviewed manuscripts and 24 biannual reports, outcomes from 10 expert meetings, and 3 books. The KIGS has shown that rhGH is safe and increases both the short-term height gain and adult height in patients with GH deficiency (GHD) and multiple other non-GHD conditions associated with short stature.